Abstract
Objective To study the efficacy and toxicities of the novel prodrug of adriamycin ( AcPhe-Lys-PABC-ADM,PADM) in the treatment of SGC-7901 gastric cancer peritoneal carcinomatosis animal models.Methods The homogenate of SGC-7901 gastric cancer tissue was intraperitoneally injected into BALB/C nude mice to build gastric cancer peritoneal carcinomatosis.Then animals were randomized into control ( n =9),adriamycin ( ADM ) ( n =10) and PADM ( n =10) groups and treated with normal saline (10 ml/kg),ADM (2 mg/kg) and PADM (7.2 mg/kg) every 4 days,respectively.The body weight,experimental peritoneal carcinomatosis index (ePCI),blood routine,biochemical parameters of major organs were studied to evaluate the efficacy and toxicities.Results The ePCI of PADM and ADM groups was 1.0 (1-4) and 1.5 (0-6) respectively.Compared to ePCI [6.0 (1-10) ] of control group,PADM and ADM reduced ePCI significantly (P ＜0.01 ).In terms of general status,PADM had no obvious effects on body weight (23.61 ± 0.80) g,while ADM significantly decreased body weight ( 18.40 ± 2.97 ) g ( P ＜0.01 ),compared to control group (24.32 ± 1.40) g.In addition,PADM reduced toxicities on the bone marrow,heart,liver,etc.,especially on the heart,while ADM showed obvious cardiotoxicity compared to control group.Conclusion PADM could inhibit the development of gastric cancer peritoneal carcinomatosis,with significant reduction in the liver,bone marrow and especially the heart toxicities. Key words: Gastric cancer peritoneal carcinomatosis; Molecular targeted therapy; Cathepsin B; Adriamycin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
